Risk factors for poor immune response to influenza vaccination in elderly people by Bellei, Nancy Cristina Junqueira et al.
www.bjid.com.br
BJID 2006; 10 (August) 269
Received on 10 March 2006; revised 3 July 2006.
Address for correspondence: Dr. Nancy Bellei. Laboratório de
Virologia Clínica, Disciplina de Doenças Infecciosas e Parasitárias,
UNIFESP. Rua Pedro de Toledo, 781, andar 15 (frente). 04039-032,
São Paulo – SP, Brasil. Phone/Fax: (+55)1150815394. E-mail:
nbellei@uol.com.br.
The Brazilian Journal of Infectious Diseases 2006;10(4):269-273.
© 2006 by The Brazilian Journal of Infectious Diseases and Contexto
Publishing. All rights reserved.
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Influenza vaccination of elderly people is efficacious and cost effective for the prevention of
influenza and its complications. Some studies have pointed out low immunogenicity in this group.
Health status has been poorly investigated as a risk factor that may influence the immune response
to influenza vaccine. We established an immunization response study of a highly-matched elderly
population in a nursing home. One-hundred-twenty subjects of Ashkenazian origin had their vaccine-
induced antibody response assessed. Good response was obtained in 30.8% (37/120), and 31.7% (38/
120) did not react. A lack of good response was found to be associated with dementia (P=0.016) in a
multivariate analysis. In addition to dementia, malnutrition was frequently observed among poor
responders, suggesting that these factors should be considered in vaccination studies.
Chemoprophylaxis in addition to vaccination for elderly presenting dementia should be considered,
particularly for those people living nursing homes.
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Some groups of patients are at increased risk for severe
complications and deaths due to pneumonia and influenza.
These include people aged 65 and over, adults and children
with chronic cardiopulmonary conditions, renal dysfunction,
metabolic disorders, or immunosuppression, and pregnant
women. During influenza epidemics, approximately 90% of
the deaths attributed to pneumonia and influenza involve older
people. Although mortality increases with age, the presence
of one high-risk medical condition increases the death rate
from pneumonia or influenza by 20-fold [1].
Vaccination is still one of the most important measures of
control against influenza, and it is generally recommended for
people with risk factors that predispose them to higher
morbidity and mortality. Currently-licensed inactivated
vaccines are safe and immunogenic, inducing immunity in 60-
90% of healthy young adults. Strong evidence has
demonstrated that influenza vaccination of persons over 65
years is efficacious and cost effective; it reduces the incidence
of disease, hospitalizations and mortality by 50% [2,3].
However, some reports have pointed out that immunogenicity
in older people is generally lower [4]. Few studies have
assessed the influence of health status in the elderly as a risk
factor for antibody response to influenza vaccination. Elderly
persons with chronic lung disease have shown inadequate
immune response rates [5]. Other underlying conditions, like
chronic stress and functional disability, have been associated
with poorer immune response to influenza vaccine [6; 7; 8].
There is a lack of information about the influence of health
status as a risk factor for antibody response to influenza
vaccination in elderly Brazilians. Recently-approved
neuraminidase inhibitors have come to the market and may be
used for prophylaxis, combined with immunization, during
outbreaks. We investigated risk factors that may influence
the immune response in influenza-vaccinated elderly people
living in a nursing home.
Material and Methods
Patients
Sera were obtained from 120 annually-vaccinated nursing
home elderly residents, before and after vaccination (28-45
days), previous to the 1999 Brazilian influenza season. The
medical ethics committee of the Sao Paulo Federal University
approved the protocol and informed consent was obtained
before enrollment.
Serology
All pre and post immunization sera obtained from the elderly
group were tested by an enzyme linked immunoassay (ELISA)
standardized in our laboratory, based on previous reports using
the same technique. Control sera included in each run were
obtained from the Adolfo Lutz Institute (the National Reference
Laboratory) and the assays were performed as follows:
Hemaglutination-inhibition test (HI): samples of  six subjects
of the healthy control group were tested for influenza
antibodies to each antigen separately (H1N1, H3N2 and B),
before and after vaccination (30 days), according to
procedures recommended by the Centers for Disease Control
and Prevention (CDC, Atlanta) in a National Reference
Laboratory for Influenza Surveillance (Instituto Adolfo Lutz,
Sao Paulo). Results from these patients were used as reference
values for the in-house ELISA.
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Enzyme immunoassay (ELISA): samples were tested by a
previously-standardized ELISA [9], as follows: polystyrene
plates were coated with vaccine antigens – A/Sydney/5/97
(H3N2), A/Beijing/262/95 (H1N1), and B/Beijing/184/93
(Vaxgripe 1999, Paster Mérieux Connaught) - and incubated
with diluted serum samples. After washing with six M Urea for
selection of high avidity antibodies, anti-human IgG-HRP was
added and optical densities (OD) read.
Patterns of antibody response were established using
values of the reference sera as follows: 1) Determination of
differences between OD values obtained for samples of pre
and post vaccination tested by EIA; 2) Comparison between
those values with HI titer results; 3) Discrimination of three
levels of OD (ELISA) results based on the cutoffs that
corresponded to three patterns of the HI test: no increase in
titers (non reactive), fourfold or more increase (good response)
and any increase lower than fourfold increase (intermediate
response), at least for one virus subtype of the vaccine mix. 4-
After this step, all 120 pre and post vaccination samples were
tested by ELISA and classified according to these cutoffs.
Risk factors
Data from multidisciplinary patient files were obtained,
including demographic information, nutritional status,
cardiovascular, pulmonary, neurological, metabolic and
hormonal disturbances, other illnesses and drug treatment.
Any episode of respiratory infections during six months after
immunization was assessed. The diagnosis of neurological
disturbances was based on neurologist evaluation. These
variables were further analyzed together with the antibody
response patterns.
Statistical analysis
Influence of risk factors were subjected to univariate and
multivariate analysis and considered statistically significant
at P<0.05. The statistical analyses were performing in SPSS
version 10.0 software. For analysis of risk factors for no
antibody response to vaccine, we initially grouped all subjects
with good response and intermediate response together.
Results
Study subjects were predominantly female (90%), with a
median age of 84.7 years (range 65 to 100 years), almost all
Ashkenazian Jews, vaccinated yearly and living in a nursing
home for 8.4 years (median). There were some differences in
the number of previous immunizations among patients, but all
subjects were immunized the year before the study.
A fourfold antibody increase in HI titres is the conventional
standard for determining a significant response to viral vaccine.
Comparison between EIA and HI from the control group
showed great correspondence and allowed us to define three
patterns of response according to the OD levels obtained
from differences between paired samples (pre and post
vaccination). According to the methodology, it was
established that those EIA values below the cutoff
(unchanged HI titres) were considered non-reactive (n= 38,
31.7%); values above 0.4 (a fourfold or greater increase in
HI) were considered highly reactive (n= 37, 30.8%), being
considered as good responders. An intermediate pattern was
obtained for 45 out of 120 participants (37.5%).
Characteristics of the study group and risk factors for
non-response to influenza antigen vaccine are shown in
Table 1. Among the 120 patients, 63 (52.5%) were considered
to have progressive dementia. The criterion of this diagnosis
was based on neurologist evaluation and included minimal
signs of mental deterioration as discrete memory alterations.
However, the great majority of the subjects presented other
impairments of neurological function. A lack of response to
influenza vaccine in this study was associated with dementia
in univariate analysis (odds ratio, OR = 0.5, 95% CI 0.2–0.9,
P=0.02 by the Fisher exact test) and in the multivariate
analysis (P=0.016) as well. In fact, 26 out of 38 (68.4%) of the
non-responder patients had dementia and 45 of 57 (78.9%)
subjects without dementia showed antibody response (data
not show).
Based on a univariate analysis, the nutritional status was
apparently a risk factor for poor immune response to influenza
vaccine. Malnutrition gave a nearly significant value of
P=0.067, but probably since most of the demented presented
with malnutrition a non-significant P value was found in the
multivariate analysis. Investigating the elderly that presented
malnutrition, only two subjects showed a good response,
while eight had an intermediate pattern and 10 were non-
responders. There was a strong correlation between
malnutrition and the three patterns of response to
vaccination (r=0.923).
Absence of antibody response to influenza vaccine
showed no correlation with respiratory infections. Indeed,
no statistical significance was demonstrated for the use of
immunomodulatory drugs (corticosteroids) or history of
infections caused by herpes virus or candidiasis. The study
population had a high incidence of chronic heart disease,
but there was no association with a failure in the immune
response to influenza vaccine, even in those elderly with
another comorbidity, such as lung disease.
Dicussion
Several reports have demonstrated low effectiveness of
standard influenza vaccination in conferring adequate
antibody response against influenza viral antigens in elderly
people. Some authors report seroconversion rates of around
30% in elderly individuals [10,11]. Seroresponse measured
by ELISA in this population showed similar results (highly
reactive in 30.8%). An intermediate pattern, which was found
in 31.7% of the aged people, had no strong association with
optimal seroconversion, as defined for this study.
Nevertheless, this intermediate response group expressed
Poor Immune Response to Influenza Vaccination
www.bjid.com.br
BJID 2006; 10 (August) 271
Table 1. Clinical status of 120 aged subjects and influenza vaccine immune response
Figure 1. Influenza vaccine immune response and dementia.
* Difference significant (P=0.020).
some immune response, but it is not clear if this indicates
protection against influenza infection. Those antibody titers
could represent previous exposure to natural influenza virus,
previous vaccination, or both [12]. The design of this study
did not allow us to characterize subjects in terms of immune
protection for those individuals that showed some antibody
response. In addition, there was a low activity of influenza
during the study period. This may explain the similar rates of
respiratory infections among subjects with different antibody
responses.
Protective efficacy of the influenza vaccine in the elderly
depends on a sufficient antigenic match between the vaccine
and epidemic viruses, on the immunogenicity of the vaccine
(viral strain) and on the health status of the vaccine recipient
[13,14]. In this study a patient group matched by age, previous
vaccination status, ethnicity (Ashkenazian Jews) and time
living in a nursing home was analyzed, and health status
became the single important variable for seroresponse of the
influenza vaccine.
Dementia was strongly correlated with poor immune
response in vaccine recipients among all the risk factors that
we analyzed. Evolution to a demential status may be the result
of multiple mechanisms occurring at the same time, and some
degenerative processes may affect the immune system. The
degenerative cortical alteration is still poorly understood and
is usually linked to functional mechanisms involving disability
in activities of daily living. These conditions provoke a
frequent need for care support for daily activities, which result
in additional frustration, depression and chronic stress. The
association between poor immune response and chronic stress
has already been described [6]. Disability in older people has
also been associated with lower immune response to influenza
vaccine [7]. Similarly, depressed older people were reported
to get cold more easily [15], and disabled depressed elderly
show reduced immunoreactivity to influenza vaccine [16]. In
addition, influenza outbreaks among nursing home residents
with disabilities could lead to important morbidity and mortality
[17]. Hence disabled and demented elderly are at higher risk
for non-response to influenza vaccine, probably for influenza
disease and influenza-related complications as well.
We did not find an increased risk for failed influenza vaccine
response among those subjects with a history of conditions
that might point to an immune depression status, such as
corticosteroid use or infections due to herpes virus and
candidiasis. All those risk factors are referred by physicians
at a very low frequency to allow assessing differences among
groups.
Nutritional deficiency and impaired immune function have
been reported in aged people, often simultaneously [18,19].
However, the relationship between these conditions is still
controversial and independence of the two phenomena has
also been reported [20]. Factors that may contribute to these
conflicting results are the several parameters proposed for
nutritional status assessment, including biochemical,
hematological, and protein markers. Some previous reports
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Clinical status Total (%) Response (n)* Non response(n)
Malnutrition 20 (16.7) 10 10
Diabetes 12 (10.0) 10 2
Dementia 63 (52.5) 37 26
Anemia 37 (30.8) 23 14
Chronic cardiac disease 47 (39.2) 33 14
Chronic lung disease 16 (13.3) 13 3
Lung and cardiac disease 57 (47.5) 41 16
Smoking 29 (24.2) 22 7
Low thyroid hormone 15 (12.5) 12 3
Respiratory infections 40 (33.3) 27 13
Herpes virus infections 3 (2.5) 2 1
Corticoids use 13 (10.8) 9 4
Candidiasis 9 (7.5) 5 4
* Response considered any increase in antibody titers (good response plus intermediate response).
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have demonstrated the beneficial influence of nutritional
support for antibody response after influenza vaccination
in the elderly [21,22]. Indeed, others have suggested the
effects of trace elements and vitamin supplementation for
increasing antibody titers and reducing influenza
infections [23,24]. In our study, malnutrition did not reach
significance as a risk factor for non-response against
influenza vaccine antigen. However, antibody pattern
analysis of each group by itself suggested that nutritional
status could influence progression of impaired immune
response, expressed by an increased rate of failure in
antibody response to influenza vaccine. These results
confirm previous studies that indicate a higher frequency
of influenza vaccine response among institutionalized
elderly with a eutrophic status [25].
Specific anti-influenza therapy has been used to control
outbreaks of influenza in older nursing home residents
[13,26]. Since vaccine efficacy may be reduced because of
impaired immune response, the risk of influenza disease
increases in nursing homes during an epidemic season.
Thus, identification of risk factors that contribute to failed
vaccine immune response, such as dementia and
malnutrition, are important in considering prophylactic
administration of antiviral agents that can provide protection
additional to that provided by vaccination [27].
In summary, we found that the frequency of non-
reactivity to influenza vaccine antigens was consistent with
published reports on elderly populations. Although the
increase in antibody titers was not optimal among subjects
with dementia and/or malnutrition, this should not be a reason
for not vaccinating them. Indeed, elderly people in a nursing
home with malnutrition and/or dementia should be
considered for antiviral chemoprophylaxis, besides
immunization, during epidemic influenza outbreaks.
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